Results 81 to 90 of about 378,578 (295)

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Consequences of Fetal Cardiac Anomalies: A Two-Year Experience in a Tertiary Perinatology Center

open access: yesClinical and Experimental Obstetrics & Gynecology
Background: This study aimed to analyze prenatally diagnosed fetal cardiac anomaly cases in a tertiary center with respect to the incidence, type of anomalies, and rate of correct diagnosis based on postnatal diagnosis (by comparing pre- versus post ...
Gokhan Bolluk   +4 more
doaj   +1 more source

A prospective pilot study of fetoscopic laser surgery for twin-to-twin transfusion syndrome between 26 and 27 weeks of gestation

open access: yesTaiwanese Journal of Obstetrics & Gynecology, 2016
Objective: The aim of this study is to clarify the feasibility and efficacy of fetoscopic laser photocoagulation of placental vascular communicating vessels (FLP) on twin–twin transfusion syndrome (TTTS) after 26 weeks of gestation. Materials and Methods:
Masahiko Nakata   +8 more
doaj   +1 more source

Hypoplastic Left Heart Syndrome: Is There a Role for Fetal Therapy? [PDF]

open access: yesFront Pediatr, 2022
Tulzer A   +6 more
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

open access: yesMolecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald   +18 more
wiley   +1 more source

New challenges of fetal therapy in Japan. [PDF]

open access: yesJ Obstet Gynaecol Res, 2022
Wada S, Ozawa K, Sago H.
europepmc   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Care Levels for Fetal Therapy Centers. [PDF]

open access: yesObstet Gynecol, 2022
Baschat AA   +22 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy